Edgewise Therapeutics Inc
NASDAQ:EWTX

Watchlist Manager
Edgewise Therapeutics Inc Logo
Edgewise Therapeutics Inc
NASDAQ:EWTX
Watchlist
Price: 29.78 USD 1.85% Market Closed
Market Cap: $3.2B

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Edgewise Therapeutics Inc
NASDAQ:EWTX
3.1B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Edgewise Therapeutics Inc
Glance View

Market Cap
3.2B USD
Industry
Pharmaceuticals

Edgewise Therapeutics Inc. is a biopharmaceutical company that has carved its niche by focusing intently on developing treatments for rare muscle disorders. Founded with the vision of addressing the unmet needs within the realm of muscular dystrophies and other rare myopathies, Edgewise aims to combat these challenges through precision medicine. Its unique approach lies in leveraging its proprietary drug discovery platform to identify and develop small molecule therapies that target the underlying causes of these muscle disorders. By honing in on the mechanistic roots of muscle dysfunction, Edgewise aspires to improve the quality of life for patients who often have limited treatment options available. The company generates revenue primarily through the successful development and potential commercialization of its therapies. As with many biopharmaceutical entities, the cornerstone of Edgewise's financial strategy is to push its drug candidates through the clinical trial phases efficiently, demonstrating safety and efficacy to obtain regulatory approval. Partnerships, collaborations, and licensing agreements often play a critical role in supplementing its revenue stream, enabling Edgewise to leverage additional resources and expertise. By addressing the therapeutic gaps in rare muscle disorders with promising candidates that have the potential to be first-in-class or best-in-class treatments, Edgewise Therapeutics strategically positions itself to create significant value for its patients and stakeholders alike.

EWTX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top